Closely monitor patients for any anginal symptoms (eg, chest pain). Not to be administered to patients w/ cerebral infraction until condition is stabilized. Discontinue use or dosage reduction if excessive increase in pulse rate is observed in patients w/ coronary artery stenosis. Risk of menorrhagia in patients during menstruation. Patients w/ bleeding tendency or predisposition to bleeding, coronary artery stenosis, DM or abnormal glucose tolerance, severe HTN w/ consistently high BP eg, malignant HTN. Patients on anticoagulants (eg, warfarin), antiplatelets (eg, aspirin or ticlopidine), thrombolytics (eg, urokinase or alteplase), or prostaglandin E1
or its derivatives (eg, alprostadil). Monitor patients for development of new systolic murmur or cardiac symptoms after starting treatment. Severe hepatic & severe renal impairment. Lactation. Childn. Elderly.